MAPK3 and melanoma: Indeed, the specific SHP-2 inhibitor 11a-1 [163], an indole salicylic acid inhibitor, reduces the aforementioned phenomena in melanoma cells by downregulating the SHP-2-mediated ERK1/2 and AKT signaling pathways.